Catalyst MedTech acquires X3D
Case News
Catalyst MedTech, a US portfolio company of Sentinel Capital Partners, has acquired 100% of the shares in X3D (formerly DDD-Diagnostic).
Plesner advised Catalyst MedTech and Sentinel Capital Partners in connection with the acquisition.
Plesner advised Catalyst MedTech and Sentinel Capital Partners in connection with the acquisition.
Catalyst MedTech, a US-based portfolio company of Sentinel Capital Partners, has acquired X3D (formerly DDD-Diagnostic), a Denmark-based manufacturer of gamma camera and SPECT imaging systems for use in nuclear cardiology and general nuclear medicine.
X3D supplies imaging systems to medical equipment companies and has an installed base of systems worldwide.
The acquisition strengthens Catalyst MedTech's imaging platform and expands its capabilities within nuclear medicine and molecular imaging.
Plesner is pleased to have acted as legal advisor to Catalyst MedTech and Sentinel Capital Partners in connection with the transaction.
Plesner's core M&A team on the transaction was Henrik Laursen, Frederik Jastrup Brodersen and Caroline Eldrup.